Literature DB >> 36240328

Canadians' (over)active contributions to overactive bladder research.

Soojin Kim1,2.   

Abstract

Entities:  

Year:  2022        PMID： 36240328      PMCID： PMC9565066          DOI： 10.5489/cuaj.8111

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   2.052


× No keyword cloud information.
  5 in total

Review 1.  Bladder and bowel dysfunction in children: An update on the diagnosis and treatment of a common, but underdiagnosed pediatric problem.

Authors:  Joana Dos Santos; Roberto I Lopes; Martin A Koyle
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

2.  EAU-ESPU guidelines recommendations for daytime lower urinary tract conditions in children.

Authors:  Serdar Tekgul; Raimund Stein; Guy Bogaert; Shabnam Undre; Rien J M Nijman; Josine Quaedackers; Lisette 't Hoen; Radim Kocvara; Mesrur Selcuk Silay; Christian Radmayr; Hasan Serkan Dogan
Journal:  Eur J Pediatr       Date:  2020-07       Impact factor: 3.183

3.  Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.

Authors:  Anne-Sophie Blais; Geneviève Nadeau; Katherine Moore; Lucie Genois; Stéphane Bolduc
Journal:  Eur Urol       Date:  2016-02-11       Impact factor: 20.096

4.  First North American experience of propiverine use in children with overactive bladder.

Authors:  Élisabeth Lapointe; Narcisse Singbo; Élizabeth Naud; Stéphane Bolduc
Journal:  Can Urol Assoc J       Date:  2022-10       Impact factor: 2.052

5.  Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.

Authors:  Helmut Madersbacher; Gerd Mürtz; Schahnaz Alloussi; Burghard Domurath; Thomas Henne; Iris Körner; Andreas Niedeggen; Joseph Nounla; Jürgen Pannek; Heinrich Schulte-Baukloh; Daniela Schultz-Lampel; Paul Bock; Gerhard Strugala
Journal:  BJU Int       Date:  2008-10-24       Impact factor: 5.588
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.